RepliCel Life Sciences, Inc.
18.10.2021 15:09:29 CEST | ACCESS Newswire | Press release
After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration data and innovations related to its cell therapy treatment for male and female pattern hair loss.
VANCOUVER, BC / ACCESSWIRE / October 18, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has retained Aceris Law LLC, a law firm specialized in international arbitration, to pursue the resolution of its disagreement with Shiseido Company Limited ("Shiseido").
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.The Company further announced that its legal counsel has now filed a Notice of Arbitration and provided a copy to Shiseido in accordance with the International Center for Dispute Resolution (ICDR) Rules, which are the arbitration rules that govern all disagreements between the parties.
The dispute between Shiseido and RepliCel is related to a license for Asia, acquired by Shiseido, to RepliCel's cell therapy technology for androgenetic alopecia, which is the leading cause of male and female pattern hair loss.
In accordance with the ICDR rules, once an arbitrator is selected and the parties have filed their claims and responses, the arbitrator will accept evidence and arguments in support of a ruling on whether or not either party materially breached the license agreement and what relief should be awarded as a result of the ruling including enforcement of the license agreement, return of the license, and/or payment of damages including the equivalent of all reasonably expected future milestone and royalty payments.
Legal counsel for RepliCel issued several demand letters to Shiseido to comply with the terms of its license agreement which RepliCel alleges Shiseido has now breached which, if not cured, could result in the return of the license to RepliCel for re-licensing to other partners in Asia.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function. These cell therapy product candidates are based on RepliCel's innovative technology, utilizing cell populations isolated from a patient's healthy hair follicles.
The Company's product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is exclusively licensed in Asia to Shiseido Company Limited. RepliCel maintains the rights to RCH-01 for the rest of the world. RCT-01 and RCS-01 are exclusively licensed in Greater China to YOFOTO (China) Health Company. RepliCel and YOFOTO are currently co-developing these products in China. RepliCel maintains the rights to these products outside of Greater China.
RepliCel has also developed a proprietary injection device, RCI-02, and related consumables, which is expected to improve the administration of its cell therapy products and certain other injectables. YOFOTO has exclusively licensed the commercial rights for the RCI-02 device and consumables in Greater China for dermatology applications and is expected to first launch the product in Hong Kong upon it being approved for market launch in either the United States or Europe. Please visit www.replicel.com for additional information.
Notable Facts:
- RepliCel's three cell therapy products have now been tested in over 100 patients in four countries on three continents.
- RepliCel now has key strategic partners in the United States, China, and Japan each of which are now investing heavily in the further clinical testing and development of RepliCel's products for their markets. Data from each of the clinical programs will strengthen the product development initiatives for RepliCel and its other partners worldwide.
For more information, please contact:
Lee Buckler, CEO and President
604-248-8693
info@replicel.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: RepliCel Life Sciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/668473/RepliCel-Files-Notice-of-Arbitration-against-Shiseido-Company-to-Resolve-its-License-Agreement-Dispute-Regarding-its-Androgenetic-Alopecia-Cell-Therapy
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New GTDC Research Illuminates Distribution's Expanding Role in Modern Technology Ecosystems29.7.2026 15:00:00 CEST | Press release
TAMPA, FL / ACCESS Newswire / July 29, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, today released a new research report, The Evolving Role of Distribution in Technology Go-To-Market Models, developed in partnership with Channelnomics. The study examines the shift in distribution from a traditional channel intermediary into a strategic operating platform that helps vendors and partners scale, increase support and overcome the complexities associated with innovation (i.e., AI and cybersecurity) and integration. According to the research, customer expectations are rising rapidly as organizations seek integrated outcomes across AI, cybersecurity, hybrid cloud, automation, analytics and managed services. Vendors and partners increasingly struggle to meet those market demands independently with solutions requiring cross-platform integration, multi-vendor coordination, lifecycle support and operational consistency. The G
TIS, EuroFinance Study Finds Corporate Treasurers Actively Evaluating AI, But Hesitant to Adopt It28.7.2026 15:00:00 CEST | Press release
The EuroFinance Deep Dive, supported by Treasury Intelligence Solutions (TIS), interviewed and surveyed corporate treasury leaders, finding that while they see AI as a powerful tool for cash forecasting, multiple concerns are deterring them from adopting it - for now. BERLIN, DE / ACCESS Newswire / July 28, 2026 / Treasury Intelligence Solutions (TIS), a best-in-class solution for payments and cash management, partnered with the research and trade association EuroFinance, in a research initiative that discovered nearly half of leading corporate finance teams are considering the use of artificial intelligence in cash forecasting - but just as many are holding off because of concerns over the technology. The EuroFinance Deep Dive, AI in Treasury: Accuracy, Intelligence and the Future of Cash Forecasting, brings together proprietary research, survey data, and perspectives from treasury leaders at Microsoft, Siemens Energy and other companies to assess where AI is creating value and where
CHAR Tech Provide Update on GazoTech's Bio-Methane Provence Project28.7.2026 14:00:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 28, 2026 / (TSXV:YES)(OTC PINK:CTRNF)(FSE:68K) GazoTech's lead project, Bio-Méthane Provence ("BMP"), an industrial-scale HTP project in France developed under the CHAR Tech / GazoTech collaboration, has successfully concluded its CNDP-supervised voluntary public consultation, with a clear majority of opinions supporting the project BMP is redeveloping the site of a former 600 MW coal-fired power plant in Gardanne, France, converting legacy fossil infrastructure into renewable energy production Once operational, BMP is expected to process 115,000 tonnes of recovered wood annually, producing 230 GWh (828,000 GJ) of RNG plus 12,000 tonnes of biocarbon, targeting commercial operations in H2 2029 CHAR Technologies Ltd. ("CHAR Tech" or "the Company"), a leader in sustainable biomass energy solutions, today provided an update on the Bio-Méthane Provence ("BMP") project in Gardanne, France, an industrial-scale High-Temperature Pyrolysis ("HTP") project bei
Giatec Completes Its First International MixPilot Fleet Roll-Out with Heidelberg Materials UK28.7.2026 11:00:00 CEST | Press release
Following a successful trial validating MixPilot in a new market, across an expanded range of truck types and slump measurement standards, Giatec and Heidelberg Materials sign a binding agreement to scale MixPilot across the Heidelberg Materials UK fleet. OTTAWA, ON / ACCESS Newswire / July 28, 2026 / Giatec, a global leader in digital concrete technology platforms, today announced that Giatec and Heidelberg Materials, one of the world's largest integrated manufacturers of heavy building materials and solutions, have scaled MixPilot across Heidelberg Materials' UK concrete operations. MixPilot was selected on the strength of two factors: superior slump accuracy, validated against other systems under real operating conditions, and driver adoption, with the superior app interface becoming a key catalyst for fleet-wide buy-in. "MixPilot delivered something simple but rare: data our team could trust from day one," said Fabrice Arriordaz, Regional Operations Manager, North Concrete, Heidelb
LiberNovo Omni SE, Omni Pro and Maxis Enter Final Week of Early Bird Launch Pricing24.7.2026 09:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / July 24, 2026 / Seven days is what remains of LiberNovo's 2026 launch pricing. Across the EU and UK, Omni SE, Omni Pro, and the Maxis series hold their early bird prices until July 31, and the window closes there. The whole lineup is built around dynamic ergonomics: the support system links the neck support, backrest, armrests, and seat, so everything moves together as you shift, lean, and recline. The chair follows the movement; you get on with the work. A quick way to choose Omni SE: the simplest build in the lineup. No motor and no battery; you set the lumbar depth by hand and the automatic support does the rest. Solid dynamic ergonomics at the friendlier price. Better Comfort, Simplified. Omni Pro: the premium chair in the lineup. Motorized lumbar adjustment and the OmniStretch guided back stretch at the press of a button, plus Active Airflow ventilation built into the seat for long days and warm rooms, an aluminum base, and Danish Gabriel fabric.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom